Bayer's Nexavar gets priority review as thyroid cancer drug (Reuters, 27 August 2013)

27 Aug 2013

The U.S. Food and Drug Administration has granted 'priority review' status, which confers an accelerated approval process, to Bayer's Nexavar to treat patients with thyroid cancer that returned despite previous surgery and treatment with radioactive iodine, according to a statement by the company.